GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 6:09 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $143.64. Biogen Idec fell $17.70 or 5.4 percent, to $309.07. Celgene Corp. fell$. 21 or. 2 percent, to $94.76.

  • Midday Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 1:18 PM ET

    Amgen Inc. fell $1.59 or 1.1 percent, to $142.50. Biogen Idec fell $23.54 or 7.2 percent, to $303.23. Celgene Corp. fell$. 60 or. 6 percent, to $94.37.

  • Early Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 10:36 AM ET

    Amgen Inc. fell $1.16 or. 8 percent, to $142.93. Biogen Idec fell $21.61 or 6.6 percent, to $305.16. Celgene Corp. rose $1.23 or 1.3 percent, to $96.20.

  • Third Point urges Amgen to consider breakup Tuesday, 21 Oct 2014 | 7:31 PM ET

    A hedge fund run by a famed investor said Tuesday it has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In response, Amgen said that its board and management are continually assessing the company's business. Third Point said Amgen Inc., which makes a range of drugs for arthritis, anemia and other diseases, is not...

  • Final Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 6:01 PM ET

    Amgen Inc. rose $6.58 or 4.8 percent, to $144.09. Biogen Idec rose $15.36 or 4.9 percent, to $326.77. Celgene Corp. rose $2.97 or 3.2 percent, to $94.97.

  • BOSTON, Oct 21- Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent. "Our own extensive diligence suggests that a breakup of Amgen is feasible and that purported constraints such as tax strategy and supply...

  • Dan Loeb talks up Amgen stake; shares rise Tuesday, 21 Oct 2014 | 3:02 PM ET
    Daniel Loeb

    Hedge fund manager Dan Loeb recommended Amgen's stock Tuesday, causing shares to rise on the news.

  • Midday Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 1:43 PM ET

    Amgen Inc. rose $1.96 or 1.4 percent, to $139.47. Biogen Idec rose $8.12 or 2.6 percent, to $319.53. Celgene Corp. rose $2.57 or 2.8 percent, to $94.57.

  • Early Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 11:56 AM ET

    Amgen Inc. rose $1.55 or 1.1 percent, to $139.06. Biogen Idec rose $6.48 or 2.1 percent, to $317.89. Celgene Corp. rose $3.34 or 3.6 percent, to $95.34.

  • Final Glance: Biotechnology companies Monday, 20 Oct 2014 | 6:05 PM ET

    Amgen Inc. rose $3.82 or 2.9 percent, to $137.51. Biogen Idec rose $4.70 or 1.5 percent, to $311.41. Celgene Corp. rose $3.88 or 4.4 percent, to $92.00.

  • Midday Glance: Biotechnology companies Monday, 20 Oct 2014 | 1:23 PM ET

    Amgen Inc. rose$. 35 or. 3 percent, to $134.04. Biogen Idec rose $3.41 or 1.1 percent, to $310.12. Celgene Corp. rose $3.24 or 3.7 percent, to $91.36.

  • Early Glance: Biotechnology companies Monday, 20 Oct 2014 | 10:40 AM ET

    Amgen Inc. rose$. 93 or. 7 percent, to $134.62. Biogen Idec rose $2.07 or. 7 percent, to $308.78. Celgene Corp. rose $1.72 or 2.0 percent, to $89.84.

  • Final Glance: Biotechnology companies Friday, 17 Oct 2014 | 6:03 PM ET

    Amgen Inc. rose $3.24 or 2.5 percent, to $133.69. Biogen Idec rose $3.97 or 1.3 percent, to $306.71. Celgene Corp. rose $1.74 or 2.0 percent, to $88.12.

  • Midday Glance: Biotechnology companies Friday, 17 Oct 2014 | 1:21 PM ET

    Amgen Inc. rose $3.30 or 2.5 percent, to $133.75. Biogen Idec rose $9.17 or 3.0 percent, to $311.91. Celgene Corp. rose $3.04 or 3.5 percent, to $89.42.

  • Early Glance: Biotechnology companies Friday, 17 Oct 2014 | 10:39 AM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $130.70. Biogen Idec rose $8.00 or 2.6 percent, to $310.74. Celgene Corp. rose $2.45 or 2.8 percent, to $88.83.

  • Final Glance: Biotechnology companies Thursday, 16 Oct 2014 | 6:02 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $130.45. Biogen Idec fell $2.95 or 1.0 percent, to $302.74. Celgene Corp. fell$. 17 or. 2 percent, to $86.38.

  • WASHINGTON, Oct 16- Medicine costs would rise if draft proposals in a Pacific Rim trade pact come into force, health and consumer rights advocates said on Thursday after the release of a leaked negotiating text. The TPP's 12 members range from the United States and Japan to Malaysia and Vietnam, where equitable access to medicine is a priority, and Australia and...

  • Midday Glance: Biotechnology companies Thursday, 16 Oct 2014 | 1:21 PM ET

    Amgen Inc. fell $1.85 or 1.4 percent, to $129.05. Biogen Idec fell $2.23 or. 7 percent, to $303.46. Celgene Corp. fell$. 18 or. 2 percent, to $86.37.

  • Early Glance: Biotechnology companies Thursday, 16 Oct 2014 | 11:35 AM ET

    Amgen Inc. fell $1.81 or 1.4 percent, to $129.09. Biogen Idec fell $2.69 or. 9 percent, to $303.00. Celgene Corp. fell $1.56 or 1.8 percent, to $84.99.

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...